Research Article

Efficacy and Safety of Lianhua Qingke Tablets in the Treatment of Mild and Common-Type COVID-19: A Randomized, Controlled, Multicenter Clinical Study

Table 3

Adverse events.

Adverse eventTreatment group
N = 72
Control group
N = 72
value

Total (N, %)7 (9.72%)11 (15.28%)0.3135
Heart dysfunction (N, %)0 (0%)1 (1.39%)
Gastrointestinal dysfunction (N, %)1 (1.39%)6 (8.33%)
Hepatobiliary dysfunction (N, %)1 (1.39%)1 (1.39%)
Infections (N, %)1 (1.39%)1 (1.39%)
Metabolic disorders (N, %)3 (4.17%)2 (2.78%)
Neurological disorders (N, %)1 (1.39%)0 (0%)
Severity[1]0.3889
 Mild (N, %)6 (8.33)11 (15.28)
 Moderate (N, %)1 (1.39)0 (0.00)
 Severe (N, %)0 (0.00)0 (0.00)
Related to treatment0.7484
 Definitely related0 (0.00)0 (0.00)
 Probably related0 (0.00)0 (0.00)
 Definitely not related1 (1.39)1 (1.39)
 Probably not related6 (8.33)8 (11.11)
 Not sure0 (0.00)2 (2.78)
 Death (N, %)0 (0.00)0 (0.00)1.0000

value, comparison between the treatment group and the control group.  < 0.05 indicates a significant difference. [1]Definition of severity: mild, confirmed cases with fever (measured or subjective) or respiratory symptoms; moderate, confirmed cases with fever (measured or subjective) or respiratory symptoms and radiographic evidence of pneumonia; severe, confirmed cases with evidence including fever, respiratory symptoms, radiographic evidence of pneumonia, and at least one of the following symptoms: respiratory distress, RR ≥30 times/min; resting state, mean oxygen saturation ≤93%; and PaO2/FiO2 ≤ 300 mmHg (1 mmHg = 0.133 kPa).